XPO1 and diffuse large B-cell lymphoma: Selinexor, an oral selective inhibitor of XPO1-mediated nuclear export, received FDA approval in June 2020 as single agent for treatment of R/R DLBCL patients who have undergone at least two lines of systemic therapy [174].